The focus will be on building a differentiated product portfolio including first-time launches designed to fulfil the unmet needs of the Indian dermatology market

Emcure Pharmaceuticals is set to cater to a growing dermatology segment in India with the formation of a wholly-owned subsidiary, Emcutix Biopharmaceuticals. As a part of this strategic initiative, Emcure's existing dermatology business will also operate under Emcutix.

With a renewed focus and a dedicated team, the newly set up entity plans to significantly expand Emcure’s offerings. The focus will be on building a differentiated product portfolio including first-time launches designed to fulfil the unmet needs of the Indian dermatology market.

CEO and MD, Emcure Pharmaceuticals, Satish Mehta stated, “The dermatology market in India, is experiencing a significant surge in both value and unit consumption. Emcure is well-positioned to cater to the unmet needs of the Indian market. With a dedicated entity, Emcure aims to concentrate on developing and introducing both prescription and consumer dermatology solutions.”

Emcutix will be spearheaded by G Sathya Narayanan, who brings with him over three decades of extensive experience in the dermatology sector, with his last stint as the Managing Director, Galderma for South Asia (including India). His notable career includes building some of the most iconic brands in prescription, consumer, and aesthetic dermatology.

Emcutix, Sathya Narayanan said, “Emcutix represents a unique opportunity with derma care solutions for healthcare professionals, patients and consumers by developing a differentiated dermatology portfolio. Building on Emcure’s legacy of innovation, I look forward to building a portfolio of products that will make a meaningful difference in skin health in India.”